Barclays
BLTE

Barclays’s Belite Bio BLTE Stock Holding History

Barclays’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
6,822
+2,646
+63% +$445K ﹤0.01% 2709
2025
Q4 		$668K Buy
+4,176
New +$495K ﹤0.01% 3690
2022
Q4 		– Sell
-6,661
Closed -$223K – 5272
2022
Q3 		$223K Buy
+6,661
New +$230K ﹤0.01% 3136

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's BLTE Position: Q1 2026 in Review

Barclays increased its Belite Bio (BLTE) stake by 63% in Q1 2026, buying an estimated $445K and bringing the position to 6,822 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

Barclays first reported a position in BLTE in Q3 2022 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Barclays held 6,822 shares of Belite Bio worth $1.09M as of Q1 2026.
  • Barclays bought 2,646 Belite Bio shares in Q1 2026, an estimated $445K.
  • Belite Bio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2709 holding.
  • Barclays first reported a position in Belite Bio in Q3 2022 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.